Glycosylated Gadolinium as Potential Metabolic Contrast Agent vs Gd-DTPA for Metabolism of Tumor Tissue in Magnetic Resonance Imaging


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Тек жазылушылар үшін

Аннотация

Modern imaging technologies such as mMRI employ contrast agents to visualize the tumor microenvironment; therefore, demand for contrast agents, with an enhanced sensitivity and tissue tumor-specific target, is very high. The purpose of this study synthesizes novel metabolic contrast agent (Gd-DTPA-DG) and evaluates accumulation in tumor tissue for early diagnostic cancer. The contrast agent was synthesized and characterized with using different techniques including dynamic light scattering, high resolution transmission electron microscopy, Fourier transform infrared spectroscopy and inductively coupled plasma atomic emission spectroscopy (ICP-AES). Finally, MRI imaging performed to determine in vitro and in vivo relaxometry. Gd-DTPA-DG was specifically investigated in tissue tumor over a 45 min in vivo because of its ability to target metabolically active tumor tissue, and comparison with conventional contrast agent [Gd-DTPA (Magnevist, Bayer-USA)]. According to the result, the maximum image signal intensity in different concentrations (0.02 to approximately 0.8 mM), longitudinal relaxation time (T1) and transverse relaxation time (T2) were obtained. Signal intensity of tumor tissue was shown at 15 and 30 min after injection reaches maximum for Gd-DTPA-DG and Gd-DTPA (Magnevist, Bayer-USA), respectively. But Gd-DTPA-DG shown signal intensity higher of Gd-DTPA (Magnevist, Bayer-USA) over 45 min, comparison with Gd-DTPA (Magnevist, Bayer-USA). Images showed metabolic contrast agent penetrate into cells and accumulated in tumor. These results showed that the novel metabolic contrast agent could become a useful tool in early detection of cancer.

Авторлар туралы

Behrooz Rafiei

Medical Imaging Center, Imam Hospital Complex, School of Medicine, Tehran University of Medical Sciences (TUMS)

Email: sara_h_68@yahoo.com
Иран, Keshavaz Blvd., Tehran, 1419733141

Banafsheh Nikfari

Medical Physics and Biomedical Engineering Department, School of Medicine, Tehran University of Medical Sciences (TUMS)

Email: sara_h_68@yahoo.com
Иран, Keshavaz blvd, 16 Azar St, Tehran, 14145

Mahsa Amirrashedi

Medical Physics and Biomedical Engineering Department, School of Medicine, Tehran University of Medical Sciences (TUMS)

Email: sara_h_68@yahoo.com
Иран, Keshavaz blvd, 16 Azar St, Tehran, 14145

Sara Heydarnezhadi

Medical Physics and Biomedical Engineering Department, School of Medicine, Tehran University of Medical Sciences (TUMS)

Хат алмасуға жауапты Автор.
Email: sara_h_68@yahoo.com
Иран, Keshavaz blvd, 16 Azar St, Tehran, 14145

Nader Riahi Alam

Medical Physics and Biomedical Engineering Department, School of Medicine, Tehran University of Medical Sciences (TUMS)

Email: sara_h_68@yahoo.com
Иран, Keshavaz blvd, 16 Azar St, Tehran, 14145

Soheila Haghgoo

Pharmaceutical Department, Food and Drug Laboratory Research Center, Food and Drug Organization (FDO), Ministry of Health

Email: sara_h_68@yahoo.com
Иран, Imam St., Valiasre Cross, Tehran, 1113615911

Hossein Ghanaati

Medical Imaging Center, Imam Hospital Complex, School of Medicine, Tehran University of Medical Sciences (TUMS)

Email: sara_h_68@yahoo.com
Иран, Keshavaz Blvd., Tehran, 1419733141

Mehdi Khoobi

Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences

Email: sara_h_68@yahoo.com
Иран, Tehran, 14176

Ensiyeh Gorji

Pharmaceutical Department, Food and Drug Laboratory Research Center, Food and Drug Organization (FDO), Ministry of Health

Email: sara_h_68@yahoo.com
Иран, Imam St., Valiasre Cross, Tehran, 1113615911

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML

© Springer-Verlag Wien, 2016